Snapshot img

Type 2 Diabetes Market Size 2025-2029

The type 2 diabetes market size is forecast to increase by USD 53.8 billion, at a CAGR of 12.2% between 2024 and 2029.

The market is experiencing significant growth due to the rising prevalence of diabetes, fueled by an increasing geriatric population. This demographic trend, coupled with the underdiagnosis of the condition, presents both opportunities and challenges for market participants. The large, untapped population of undiagnosed individuals represents a significant market opportunity for innovative diagnostic solutions. However, the low diagnosis rate also poses a challenge, as untreated diabetes can lead to severe health complications and increased healthcare costs. The geriatric population, with its higher susceptibility to diabetes, further exacerbates this challenge.
To capitalize on the market opportunities and navigate these challenges effectively, companies must focus on developing innovative diagnostic tools and effective patient education programs. By addressing the unmet needs in diabetes diagnosis and management, market participants can differentiate themselves and capture a larger share of this growing market.

What will be the Size of the Type 2 Diabetes Market during the forecast period?

Explore in-depth regional segment analysis with market size data - historical 2019-2023 and forecasts 2025-2029 - in the full report.
Request Free Sample

The market continues to evolve, driven by advancements in diabetes management, public health, and weight management. Pancreatic beta-cell destruction and the subsequent need for insulin therapy remain at the forefront of market dynamics. Diabetes burden is a significant concern, with diabetic nephropathy, diabetic retinopathy, and diabetic neuropathy posing significant health risks. SGLT2 inhibitors have emerged as a promising treatment option, addressing both glycemic control and cardiovascular disease. Healthcare access and access to care are crucial factors shaping the market. Global health initiatives and healthcare costs are influencing the development of diabetes technology, including insulin delivery devices, glucose sensors, and remote monitoring.

Precision medicine, data analytics, and machine learning are transforming diabetes education and patient engagement. Lifestyle modifications, such as dietary changes and physical activity, remain essential components of diabetes management. Insulin resistance, insulin therapy, and HbA1c testing continue to be key areas of focus in the medical device industry. Ongoing research in areas like Genetic Testing, Stem Cell Therapy, and primary care physician engagement is further shaping the market. Health disparities, early detection, and glycemic control are critical public health concerns. Diabetes prevention and healthcare provider collaboration are essential to improving health outcomes. The market is continually unfolding, with ongoing drug development, clinical trials, and advancements in diabetes technology driving innovation.

How is this Type 2 Diabetes Industry segmented?

The type 2 diabetes industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Drug Class

  Insulin
  DPP-4 inhibitor
  GLP-1 receptor agonists
  SGLT-2 inhibitors
  Others


Distribution Channel

  Retail pharmacies
  Hospital pharmacies
  Online pharmacies


Delivery Mode

  Oral
  Injectable
  Continuous glucose monitoring (CGM)


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    Italy
    UK


  APAC

    China
    India
    Japan
    South Korea


  Rest of World (ROW)

.

By Drug Class Insights

The insulin segment is estimated to witness significant growth during the forecast period.

Type 2 diabetes is a complex condition characterized by insulin resistance and pancreatic beta-cell dysfunction, leading to elevated blood glucose levels. Metabolic syndrome, an autoimmune disease, and a precursor to type 2 diabetes, affects millions worldwide. The medical device industry is responding with innovative solutions, such as artificial pancreas systems and insulin delivery devices, to improve glycemic control and enhance quality of life. Artificial intelligence and machine learning are revolutionizing diabetes management by facilitating early detection, personalized treatment plans, and remote monitoring. Diabetes burden is significant, with complications including diabetic foot ulcers, diabetic retinopathy, diabetic neuropathy, and diabetic nephropathy.

Prevention and management involve lifestyle modifications, such as dietary changes and physical activity, as well as pharmacological interventions, including oral antidiabetic medications, insulin therapy, and newer classes like GLP-1 re

The Report Covers US Diabetes Devices Companies and It is Segmented by Management Devices (insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Insulin Disposable Pens, and Jet Injectors) and Monitoring Devices (self-Monitoring Blood Glucose and Continuous Glucose Monitoring). The Report Offers the Value (in USD) for the Above Segments.

The global obesity-diabetes drugs market is estimated to be worth USD 56,739.0 million in 2024 and is projected to reach a value of USD 97,567.47 million by 2034, expanding at a CAGR of 5.6% over the assessment period.

Attributes	Description
Estimated Global Obesity-Diabetes Drugs Market Size (2024E)	USD 56,739.0 million
Projected Global Obesity-Diabetes Drugs Market Value (2034F)	USD 97,567.4 million
Value-based CAGR (2024 to 2034)	5.6%

Country-wise Insights

Countries	CAGR 2024 to 2034
The United States	4.7%
China	5.7%
Germany	3.8%
The United Kingdom	4.0%
India	6.4%

Category-Wise Insights

Segment	Drug Therapy (Therapy Type)
Value Share (2024)	55.9%

Segment	Institutional Sales (Sale Channel)
Value Share (2024)	39.7%

The global diabetes care devices market is expected to reach USD 64.5 billion in 2024. The sales are expected to grow even higher and will be estimated at USD 117.7 billion in 2034 due to the rising diabetes population. The diabetes care devices market is anticipated to record a CAGR of 6.2% between 2024 and 2034.

Attributes	Description
Estimated Global Diabetes Care Devices Market Size (2024E)	USD 64.5 billion
Projected Global Diabetes Care Devices Market Value (2034F)	USD 117.7 billion
Value-based CAGR (2024 to 2034)	6.2%

Semi-annual Industry Update

Particular	Value CAGR
H1	5.7% (2023 to 2033)
H2	5.2% (2023 to 2033)
H1	4.5% (2024 to 2034)
H2	4.2% (2024 to 2034)

Country-wise Insights

Countries	CAGR 2024 to 2034
India	8.8%
China	8.4%
South Korea	8.1%
Australia	6.7%
France	4.3%
United States	3.4%

Category-wise Insights

Segment	Glucose Monitoring Devices (Product Type)
Value Share (2024)	58.3%

Segment	Diabetes Type II (Indication)
Value Share (2024)	19.7%

The diabetes market is projected to reach $6.86 billion in 2025, driven by increasing prevalence of diabetes and growing demand for advanced diabetes management devices and treatments. The market is expected to grow at a CAGR of 6.08% during the forecast period 2025-2033. Rising incidence of diabetes, coupled with technological advancements and increasing healthcare expenditure, contribute to the market growth. Key trends in the diabetes market include the rising prevalence of Type 2 diabetes due to factors such as obesity, unhealthy diet, and lack of physical activity. The market is also witnessing increased adoption of continuous glucose monitoring (CGM) devices and insulin pumps, along with a growing trend towards personalized diabetes management. Key market players such as Novo Nordisk, USV Private Limited, and Sanofi are investing in research and development to bring innovative products and solutions to the market, further driving growth in the diabetes market. Key drivers for this market are: Increasing Focus on Personal Health and Well Being, Growing Interest in Holistic and Alternative Healing Practices. Potential restraints include: High Cost Associated with Wellness Travel. Notable trends are: Rise in Usage of Online Travel Agencies Driving the Market.

The North America Diabetes Drugs Market Report is Segmented by Drug Class (Insulins [Biosimilar Insulin and More], Non-Insulin Injectable, Oral Anti-Diabetic and Combination Drugs), Diabetes Type (Type 1 Diabetes and Type 2 Diabetes), Drug Origin (Branded and Generic/Biosimilar), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and More) and Geography. The Market Forecasts are Provided in Terms of Value (USD).

The type 1 diabetes market size was valued at USD 7.90 Billion in 2024, driven by the increasing prevalence of diabetes across the 7 major markets. The market size is anticipated to grow at a CAGR of 6.80% during the forecast period of 2025-2034 to achieve a value of USD 15.25 Billion by 2034.

The global gestational diabetes market is projected to exceed USD 19,811.32 Mn by 2032, advancing from USD 9,870.25 Mn in 2024, with an estimated growth of USD 10,592.57 Mn in 2025, at a CAGR of 9.1% from 2025 to 2032.

The global pediatric diabetes therapeutic market is set to reach USD 1,633.8 million in 2024. Projections indicate that the sector is anticipated to elevate to USD 2,612.4 million by 2034. The industry stood at USD 1,540.2 million in 2023 and is anticipated to exhibit a Y-o-Y growth of 6.1% in 2024. Demand for pediatric diabetes therapeutics is slated to surge at a 4.8% CAGR.

Attributes	Description
Estimated Global Pediatric Diabetes Therapeutic Market Size (2024E)	USD 1,633.8 million
Projected Global Pediatric Diabetes Therapeutic Market Value (2034F)	USD 2,612.4 million
Value-based CAGR (2024 to 2034)	4.8%

Country-wise Insights

Countries	CAGR 2024 to 2034
United States	5.4%
China	5.3%
Germany	4.8%
United Kingdom	4.4%
India	4.5%

Category-wise Insights

Segment	Type 1 (Diabetes)
Value Share (2024)	56.2%

Segment	Insulin Therapy (Therapy)
Value Share (2024)	57.2%

The diabetes market encompasses a wide array of products catering to diverse needs across the spectrum of diabetes management:Medications: This segment includes oral hypoglycemic agents, various insulin formulations (rapid-acting, long-acting, etc.), GLP-1 receptor agonists, SGLT2 inhibitors, and other emerging drug classes.Devices: This crucial segment includes blood glucose monitoring (BGM) devices (both self-monitoring and professional-grade), insulin pumps (including both traditional and advanced technologies), continuous glucose monitoring (CGM) systems, and insulin pens.Other Products and Services: This category encompasses essential supplies such as test strips, lancets, and other consumables, along with diabetes management software, mobile applications, and telehealth services that aid in remote monitoring and patient engagement.

Global Type 1 Diabetes market size is expected to reach $22.7 billion by 2029 at 13.6%, segmented as by rapid acting insulin analogs, insulin lispro, insulin aspart, insulin glulisine

Diabetes Care Service Market Outlook

The global diabetes care service market size is projected to witness significant growth, expanding from USD 25.8 billion in 2023 to USD 45.6 billion by 2032, at a compound annual growth rate (CAGR) of 6.5%. Key growth factors driving this market include the rising prevalence of diabetes, increasing awareness about diabetes management, and technological advancements in diabetes care services.

The rising prevalence of diabetes across the globe is a major growth factor for the diabetes care service market. According to the International Diabetes Federation, the number of adults living with diabetes was approximately 463 million in 2019 and is expected to rise to 700 million by 2045. This alarming increase necessitates efficient diabetes care services, including diagnostic, treatment, and consultation services, to manage this chronic condition effectively. Additionally, lifestyle changes, increased consumption of unhealthy food, and a rise in obesity rates contribute to the growing number of diabetes cases, further driving the demand for comprehensive diabetes care services.

Technological advancements in diabetes care services are revolutionizing the market. Innovations such as continuous glucose monitoring systems, insulin pumps, and telemedicine services have significantly improved diabetes management. These technologies provide real-time data, enabling better glucose control and reducing the risk of complications. Moreover, the integration of artificial intelligence and machine learning in diabetes care provides personalized treatment plans, enhancing patient outcomes. The adoption of these advanced technologies by healthcare providers and patients is a critical factor propelling the growth of the diabetes care service market.

Increasing awareness about diabetes management and the importance of early diagnosis is also driving market growth. Governments and health organizations worldwide are implementing various programs and campaigns to educate people about diabetes prevention and management. These initiatives aim to reduce the incidence of diabetes-related complications and improve the quality of life for those affected by the condition. Additionally, healthcare providers are emphasizing the importance of regular check-ups and screenings, leading to a higher demand for diabetes care services. The growing emphasis on preventive healthcare practices is expected to further boost market growth.

The regional outlook for the diabetes care service market shows significant growth potential in various regions. North America dominates the market, driven by the high prevalence of diabetes, advanced healthcare infrastructure, and favorable government initiatives. The Asia Pacific region is expected to witness the fastest growth during the forecast period due to the increasing diabetic population, rising healthcare expenditure, and growing awareness about diabetes management. Europe also holds a substantial market share, attributed to the presence of well-established healthcare systems and supportive government policies. The Middle East & Africa and Latin America regions are gradually emerging as potential markets, driven by improving healthcare infrastructure and rising awareness about diabetes care.

Service Type Analysis

The diabetes care service market can be segmented by service type into Consultation Services, Diagnostic Services, Treatment Services, Education and Training Services, and Others. Consultation services play a pivotal role in diabetes management, as they provide personalized care plans, lifestyle modification advice, and regular monitoring. These services are essential for preventing complications and ensuring optimal health outcomes for diabetic patients. The increasing patient awareness about the importance of regular consultations and the growing number of healthcare providers offering these services are driving the segment's growth.

Diagnostic services are another critical component of the diabetes care service market. These services include blood glucose testing, HbA1c testing, urine analysis, and other diagnostic procedures essential for early detection and ongoing monitoring of diabetes. The rising prevalence of diabetes and the growing emphasis on early diagnosis and regular monitoring are fueling the demand for diagnostic services. Technological advancements, such as point-of-care testing devices and continuous glucose monitoring systems, are further enhancing the efficiency and accuracy of these services, contributing to market growth.

Treatment services encompas

Snapshot img

Diabetes Management Devices Market Size 2024-2028

The diabetes management devices market size is forecast to increase by USD 13.98 bn at a CAGR of 7.68% between 2023 and 2028.

The market is witnessing significant growth due to the rising global burden of diabetes and the increasing focus on advanced technologies such as artificial pancreas systems. These systems utilize insulin pumps and continuous glucose monitoring sensors to automatically adjust insulin delivery based on real-time glucose levels. Additionally, the integration of artificial intelligence and data analytics in diabetes management devices is revolutionizing the industry, enabling remote patient monitoring and personalized treatment plans. Other trends include the development of insulin pens with advanced features and the adoption of spectroscopy technology for non-invasive blood glucose monitoring. However, the prohibitive cost of diabetes care devices remains a major challenge for market growth.Overall, the market is expected to experience robust growth In the coming years, driven by technological advancements and the increasing prevalence of diabetes.

What will be the Size of the Diabetes Management Devices Market during the Forecast Period?

Request Free SampleThe market encompasses a range of technologies designed to assist individuals in managing their diabetes, including insulin delivery devices, mobile health applications, and disease management tools. With the global diabetic population projected to reach over 592 million by 2035, driven by factors such as obesity rates, smoking, and high cholesterol levels, the market for diabetes care devices is experiencing significant growth. Hospitals and specialty clinics are increasingly adopting minimally invasive devices, such as diabetes lancet devices and diabetes tracker devices, to improve patient care and outcomes. Type 1 diabetes, an autoimmune disease characterized by insulin deficiency, and Type 2 diabetes, often associated with insulin resistance, both require ongoing management to prevent complications, including kidney failure, gangrene, and lower limb amputation.Insulin delivery devices, including insulin pens and blood glucose level monitoring systems, are essential tools in managing both types of diabetes. The market for diabetes management devices is expected to continue expanding as technology advances and the global population ages.

How is this Diabetes Management Devices Industry segmented and which is the largest segment?

The diabetes management devices industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments. ProductBlood glucose monitoring devicesInsulin delivery systemsDistribution ChannelOfflineOnlineGeographyNorth AmericaUSEuropeGermanyUKFranceAsiaChinaRest of World (ROW)

By Product Insights

The blood glucose monitoring devices segment is estimated to witness significant growth during the forecast period. Diabetes management devices play a crucial role in monitoring and managing blood glucose levels for individuals with diabetes. These devices include a range of products such as insulin delivery systems, continuous monitoring systems, and glucose monitoring devices. Insulin delivery devices, including insulin pumps and pens, facilitate precise insulin administration. Continuous monitoring systems, such as continuous glucose monitoring systems (CGMs) and Mobi insulin pumps, provide real-time glucose level data through wireless transmission and dedicated apps. Glucowear, a continuous glucose monitoring system, offers non-invasive transdermal sensors and spectroscopy technology. Hospital pharmacies, retail pharmacies, and online pharmacies stock these diabetes care devices. The increasing prevalence of diabetes among the obese, elderly population, and those with conditions like high cholesterol levels, smoking, and inactive lifestyles necessitates effective diabetes management.Disease management is essential to prevent complications like kidney failure, gangrene, lower limb amputation, heart attack, blindness, and stroke. Diabetes tracker devices, such as diabetes monitoring software and artificial pancreas systems, help healthcare providers analyze glucose patterns and create treatment plans. User-friendly interfaces, visual representations, and medication adherence features enhance the efficacy of treatment. In summary, diabetes management devices, including insulin delivery devices, continuous monitoring systems, and glucose monitoring devices, are essential tools for managing diabetes and preventing complications. These devices offer precision, flexibility, and smart features, making diabetes care more accessible and convenient for individuals with diabetes. Hospital segment, diagnostic centers, diabetes clinics, and health

Global Type 2 Diabetes market size is expected to reach $72.22 billion by 2029 at 8.6%, segmented as receptor agonists, liraglutide, semaglutide, dulaglutide, exenatide

Type 1 Diabetes Market valued at USD 16.97 Bn in 2025, is anticipated to reaching USD 26.22 Bn by 2032, with a steady annual growth rate of 6.4%.

According to Cognitive Market Research, the global Type 2 Diabetes Mellitus Therapeutic market size will be USD 19514.5 million in 2024. It will expand at a compound annual growth rate (CAGR) of 8.80% from 2024 to 2031.

North America held the major market share for more than 40% of the global revenue with a market size of USD 7805.80 million in 2024 and will grow at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2031.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD 5854.35 million.
Asia Pacific held a market share of around 23% of the global revenue with a market size of USD 4488.34 million in 2024 and will grow at a compound annual growth rate (CAGR) of 1.8% from 2024 to 2031.
Latin America had a market share of more than 5% of the global revenue with a market size of USD 975.73 million in 2024 and will grow at a compound annual growth rate (CAGR) of 8.2% from 2024 to 2031.
Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD 390.29 million in 2024 and will grow at a compound annual growth rate (CAGR) of 8.5% from 2024 to 2031.
The SGLT2 inhibitors category is the fastest growing segment of the Type 2 Diabetes Mellitus Therapeutic industry

Market Dynamics of Type 2 Diabetes Mellitus Therapeutic Market

Key Drivers for Type 2 Diabetes Mellitus Therapeutic Market

Growing Prevalence of Type 2 Diabetes to Boost Market Growth

The rising incidence of type 2 diabetes globally is a significant driver for the therapeutic market. With lifestyle changes such as poor diet, lack of exercise, and increasing rates of obesity, the number of people diagnosed with type 2 diabetes has surged in recent years. The World Health Organization (WHO) and other health bodies have noted a steady increase in diabetes cases, particularly in developing nations, due to urbanization and changing dietary habits. As the disease burden grows, the demand for effective therapies, including oral medications, insulin, and emerging treatments like GLP-1 receptor agonists, has intensified. Pharmaceutical companies are responding to this demand by advancing research, improving drug efficacy, and focusing on developing treatments that address underlying risk factors, such as insulin resistance. This expanding patient pool drives market growth, making it a lucrative sector for therapeutic advancements. For instance, Pfizer Inc. announced its commitment to advancing a late-stage oral glucagon-like peptide-1 receptor agonist (GLP-1-RA) candidate into further clinical development. This innovative therapy aims to address obesity and diabetes in adults, reflecting Pfizer's intentions to expand treatment options for these prevalent conditions

Advancements in Diabetes Management Technology to Drive Market Growth

Advancements in diabetes management technology, such as continuous glucose monitoring (CGM) systems and insulin pumps, are driving the type 2 diabetes therapeutic market. These technologies have revolutionized how patients manage their blood glucose levels and improve treatment outcomes. With more accurate monitoring and real-time feedback, patients can better control their diabetes and avoid complications. Furthermore, digital health tools like mobile apps and telemedicine platforms have become integral parts of diabetes management, making treatment more accessible and efficient. As these technologies evolve, they create new opportunities for targeted therapeutic solutions, including combination therapies that integrate medication with digital health solutions. This innovation not only improves patient adherence to prescribed regimens but also boosts demand for more personalized, effective treatment options, contributing to the overall growth of the therapeutic market.

Restraint Factor for the Type 2 Diabetes Mellitus Therapeutic Market

High Treatment Costs and Accessibility Will Limit Market Growth

One of the major restraining factors for the Type 2 diabetes mellitus therapeutic market is the high cost of treatment, particularly with newer medications and advanced insulin therapies. Innovative treatments like SGLT2 inhibitors, GLP-1 receptor agonists, and insulin pumps can be expensive, leading to financial burdens for patients, especially in low-income regions. Additionally, healthcare systems with limited budgets may prioritize other medical needs, further hindering accessibil...

The Diabetes Care Devices Market is Segmented by Management Devices (Insulin Pumps, Insulin Syringes, and More), Monitoring Devices (Self-Monitoring Blood Glucose and Continuous Glucose Monitoring), by Patient Type (Type-1 Diabetes, Type-2 Diabetes and More), by End User (Hospitals & Clinics, Home-Care Settings and More) and Geography. The Market Forecasts are Provided in Terms of Value (USD) and Volume (units).

The type 2 diabetes market was valued at USD 35.00 Billion in 2024, driven by the rising prevalence of type 2 diabetes across the 8 major markets. The market is expected to grow at a CAGR of 8.40% during the forecast period of 2025-2034, with the values likely to rise from USD 78.41 Billion by 2034.

Diabetes Drug Market will reach USD 163.79 billion by 2034, expanding at a CAGR of 7.0 %.

As per Cognitive Market Research's latest published report, the Global Diabetes nutrition market size was USD 5,567.2 million in 2022. Diabetes nutrition Industry's Compound Annual Growth Rate will be 6.9% from 2023 to 2030. Factors Impacting on Diabetes Nutrition Market

The increasing prevalence of diabetes due to unhealthy lifestyles among people is forecasted to dominate the global diabetes nutrition market. In addition, increased product launches by major market players coupled with the easy availability of diabetic and dietary food are forecasted to dominate the global market. Furthermore, the development of innovative diabetic nutritional products will provide an opportunity for the global market. However, a lack of awareness regarding nutritional deficiency among the diabetic population may hamper the global market growth. What is Diabetes Nutrition?

Diabetic nutrition is dietary products that have low carbohydrate and sugar content and help in controlling glucose levels in the blood. Diabetes is a disease defined as high blood sugar levels resulting from insufficient insulin or a lack of cell response to the insulin produced by the body. Furthermore, diabetes damages various other body parts such as the nerves, kidneys, brain, eyes, and feet. Food products such as whole grains, millet baked sweet potato, brown rice, quinoa, and oatmeal are considered healthy foods for people who have diabetes.